Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Cansino Biologics Inc
UndervaluedConclusion
🧐 Incertitude extrême, risque très élevé, étudiez tous les aspects avec grande attention, il y a évidemment des entreprises plus transparentes comme alternative.
Similar to Cansino Biologics Inc
COLL
Collegium Pharmaceutical Inc603567
Heilongjiang ZBD Pharmaceutical Co Ltd
PBH
Prestige Brand Holdings IncSTAR
Strides Pharma Science LimitedMVP
Medical Developments InternationalCansino Biologics Inc
6185CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China. Address: 401-420, Biomedical Park, Tianjin, China, 300457
Analytics
Objectif de Cours de WallStreet
445.89 CNYRatio C/B
–Rendement du dividende
–Chiffres clés 6185
- Marge Bénéficiaire
- Revenu Total
- Bénéfice Brut
- Revenu Net
Analyse des dividendes 6185
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y>5 - expected 5-9 dividend yield on cost over 10Y<5 - expected <5 dividend yield on cost over 10YMaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
122.00 %Historique des dividendes 6185
- Ratio de Distribution
- Dividends
- Rendement du dividende
Valorisation des titres 6185
- Prix sur Revenu
- Ratio PE
- Prix sur Valeur Comptable
- Ratio de Liquidité Courante
- Ratio d'Endettement
financières 6185
Résultats | 31.12.2017 | 31.12.2018 | 31.12.2019 | 31.12.2020 | 31.12.2021 | 31.12.2022 | 31.12.2023 | Dynamique | |
Revenu Total | - | 1 135 260 CNY | 5 758 057 CNY | 18 597 470 CNY | 4 312 099 908 CNY | 1 034 013 933 CNY | 346 177 303 CNY | ||
Revenu Opérationnel | -75 821 994 CNY | -151 657 029 CNY | -204 796 814 CNY | -441 592 640 CNY | 1 807 057 545 CNY | -1 452 745 847 CNY | -2 084 900 384 CNY | ||
Revenu Net - (CF) | -64 635 836 CNY | -138 679 719 CNY | -157 218 018 CNY | -397 781 673 CNY | 1 919 910 014 CNY | -912 053 280 CNY | -1 487 007 361 CNY | ||
BPA de Base Normalisé | -0.04 CNY | -0.09 CNY | -0.10 CNY | -0.22 CNY | 1.07 CNY | -0.51 CNY | -0.83 CNY | ||
Dividende par Action | 0.00 CNY | 0.00 CNY | 0.00 CNY | 0.00 CNY | 0.00 CNY | 0.80 CNY | 0.00 CNY | ||
Ratio de Distribution | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 121.78 % | 0.00 % | ||
Total des Actifs | 868 862 099 CNY | 798 169 849 CNY | 1 789 643 478 CNY | 6 767 530 628 CNY | 11 908 425 437 CNY | 11 502 029 994 CNY | 9 345 639 057 CNY | ||
Total des Passifs | 259 778 899 CNY | 294 404 454 CNY | 314 887 344 CNY | 679 171 715 CNY | 3 335 894 172 CNY | 4 235 535 772 CNY | 4 042 978 146 CNY | ||
Ratio d'Endettement | 0.30 | 0.37 | 0.18 | 0.10 | 0.28 | 0.37 | 0.43 | ||
Total des Actifs Courants | 428 148 989 CNY | 221 641 245 CNY | 796 535 885 CNY | 5 436 273 066 CNY | 9 316 630 652 CNY | 7 752 474 480 CNY | 5 195 766 576 CNY | ||
Total des Passifs Courants | 113 252 617 CNY | 106 992 614 CNY | 116 764 062 CNY | 410 648 673 CNY | 2 869 667 703 CNY | 2 933 141 202 CNY | 2 599 317 410 CNY | ||
Ratio de Liquidité Courante | 3.78 | 2.07 | 6.82 | 13.24 | 3.25 | 2.64 | 2.00 | ||
Ratio de Liquidité Immédiate | 3.77 | 1.99 | 6.68 | 12.82 | 2.94 | 2.41 | 1.86 | ||
Rendement des Actifs | -7.44 % | -17.37 % | -8.78 % | -5.88 % | 16.12 % | -7.93 % | -15.91 % | ||
Couverture des Intérêts FFO | - | - | -18.36 | -19.54 | 87.37 | -36.64 | -36.64 * | ||
Ratio C/B - P/E (LTM) | - | - | - | -258.96 | 44.16 | -41.35 | -12.68 | ||
Rendement du dividende (LTM) | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.53 % | 0.00 % | ||
Rendement de Rachat (LTM) | - | - | -2.04 % | -11.14 % | - | - | - |